SuperGen Submits First NDA Module for Pancreatic Cancer Drug

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 2
Volume 12
Issue 2

DUBLIN, California-Super-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.

DUBLIN, California—Super-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.

Articles in this issue
COX-2 Inhibitors Decrease Toxicity due to Chemotherapy; May Help Arrest Tumor Progression
Some Activity for Gefitinib in Heavily Pretreated Breast Cancer
Brachytherapy Results Similar for Blacks, Whites
Dose-Dense Chemo Ups Survival in Node+ Breast Cancer
MR Spectroscopy IDs Breast Cancers, Node Involvement
ODAC Wants More Data on Expanded Casodex Indication
SuperGen Submits First NDA Module for Pancreatic Cancer Drug
Two Added to ONI’s Oncology Nursing Editorial Advisory Board
Bortezomib Active in Relapsed/Refractory Myeloma
Telomerase Potential Cancer Biomarker
Developing Targeted Therapy More Difficult Than Anticipated
Preoperative Chemoradiotherapy Downsizes 100% of Rectal Tumors in Phase I/II Trial
Fluorouracil/Leucovorin Maintains Leading Role, Results of Three-Drug Regimens Are Pending
Adjuvant Therapy for Rectal Cancer Still Needed in Node-Positive Cases
Adding Bevacizumab to IFL Combination Does Not Significantly Alter IFL Toxicity
Recent Videos
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Related Content
Phase 3 EMERALD-1 trial results reveal that no new adverse events were identified with durvalumab plus bevacizumab in patients with unresectable HCC.

Durvalumab Plus Bevacizumab Improves PFS Outcomes in Unresectable HCC

Roman Fabbricatore
January 17th 2025
Article

Phase 3 EMERALD-1 trial results reveal that no new adverse events were identified with durvalumab plus bevacizumab in patients with unresectable HCC.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Adding lenvatinib/pembrolizumab to TACE elicits a numerical overall survival improvement in the LEAP-012 trial, although additional follow-up is necessary.

TACE Plus Lenvatinib/Pembrolizumab Boosts PFS in Unresectable Liver Cancer

Russ Conroy
January 16th 2025
Article

Adding lenvatinib/pembrolizumab to TACE elicits a numerical overall survival improvement in the LEAP-012 trial, although additional follow-up is necessary.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

The decision follows safety data from the phase 1/2 LOKON001 trial evaluating LOAd703 in advanced pancreatic ductal adenocarcinoma.

LOAd703 Receives FDA Fast Track Designation for Pancreatic Cancer

Roman Fabbricatore
January 13th 2025
Article

The decision follows safety data from the phase 1/2 LOKON001 trial evaluating LOAd703 in advanced pancreatic ductal adenocarcinoma.

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.

Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC

Russ Conroy
January 10th 2025
Article

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.